On this page of StockholderLetter.com we present the latest annual shareholder letter from ARTIVION, INC. — ticker symbol AORT. Reading current and past AORT letters to shareholders can bring important insights into the investment thesis.
2024 2024 Annual Report to Stockholders NYSE: AORT www.artivion.com
1655 Roberts Boulevard, N.W. Kennesaw, GA 30144 PHONE: (770) 419-3355 FAX: (770) 429-5250 E-MAIL: info@artivion.com www.artivion.com FORM 10-K Included in this Annual Report to Stockholders is a copy of the Company s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including certifications by the Chief Executive Officer and Chief Financial Officer, but excluding additional exhibits, as filed with the Securities and Exchange Commission. Additional copies of this Annual Report and the Form 10-K, without exhibits, are available at no charge. Please send requests to: Corporate Secretary Artivion, Inc. 1655 Roberts Boulevard, NW Kennesaw, GA 30144 STOCKHOLDER COMMUNICATIONS Directors may be contacted by mail, addressed c/o Corporate Secretary at the address provided above for requesting copies of the Form 10-K. STOCK LISTINGS Artivion, Inc. Common Stock is traded on the New York Stock Exchange under the symbol AORT. NEW YORK STOCK EXCHANGE ANNUAL CEO CERTIFICATION The Chief Executive Officer of Artivion, Inc. provided the New York Stock Exchange with an unqualified Annual CEO Certification last year. TRANSFER AGENT Communications regarding change of address, transfer of stock ownership, or lost stock certificates should be directed to: Equinity Trust Company, LLC 55 Challenger Road Floor 2 Ridgefield Park, NJ 07660 Phone: 800-468-9716 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Ernst & Young LLP Suite 1000 55 Ivan Allen Jr. Boulevard Atlanta, GA 30308
 • shareholder letter icon 4/1/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/5/2023 AORT Stockholder Letter
 • stockholder letter icon 4/1/2024 AORT Stockholder Letter
 • stockholder letter icon More "Medical Instruments & Supplies" Category Stockholder Letters
 • Benford's Law Stocks icon AORT Benford's Law Stock Score = 95


AORT Shareholder/Stockholder Letter Transcript:

2024
2024 Annual Report to Stockholders
NYSE: AORT
www.artivion.com

1655 Roberts Boulevard, N.W. Kennesaw, GA 30144
PHONE: (770) 419-3355
FAX: (770) 429-5250
E-MAIL: info@artivion.com
www.artivion.com
FORM 10-K
Included in this Annual Report to
Stockholders is a copy of the Company   s Annual
Report on Form 10-K for the fiscal year ended
December 31, 2024, including certifications by
the Chief Executive Officer and Chief Financial
Officer, but excluding additional exhibits, as filed
with the Securities and Exchange Commission.
Additional copies of this Annual Report and the
Form 10-K, without exhibits, are available at no
charge. Please send requests to:
Corporate Secretary
Artivion, Inc.
1655 Roberts Boulevard, NW
Kennesaw, GA 30144
STOCKHOLDER COMMUNICATIONS
Directors may be contacted by mail,
addressed c/o Corporate Secretary at the address
provided above for requesting copies of the
Form 10-K.
STOCK LISTINGS
Artivion, Inc. Common Stock is traded on
the New York Stock Exchange under the symbol
AORT.
NEW YORK STOCK EXCHANGE ANNUAL
CEO CERTIFICATION
The Chief Executive Officer of Artivion,
Inc. provided the New York Stock Exchange with
an unqualified Annual CEO Certification last
year.
TRANSFER AGENT
Communications regarding change of
address, transfer of stock ownership, or lost stock
certificates should be directed to:
Equinity Trust Company, LLC
55 Challenger Road
Floor 2
Ridgefield Park, NJ 07660
Phone: 800-468-9716
INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
Ernst & Young LLP
Suite 1000
55 Ivan Allen Jr. Boulevard
Atlanta, GA 30308



shareholder letter icon 4/1/2025 Letter Continued (Full PDF)
 

AORT Stockholder/Shareholder Letter (ARTIVION, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2026, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.